Skip to content

Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models

Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07767565
Enrollment
40
Registered
2026-08-17
Start date
2026-09-15
Completion date
2027-12-31
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Exercise and Recovery

Brief summary

The goal of this observational study is to develop and evaluate a large language model (LLM)-based decision support system for exercise prescription in breast cancer patients, aiming to provide personalized decision-making support for postoperative breast cancer rehabilitation. The main questions it aims to answer are: How accurate, personalized, and safe are the exercise prescriptions generated by the fine-tuned LLM? How does the model's performance compare with other mainstream or non-fine-tuned models across different stages and subtypes of breast cancer? Participants are postoperative breast cancer rehabilitation patients treated at Sun Yat-sen Memorial Hospital of Sun Yat-sen University. They will have demographic, tumor, treatment, and physical fitness data collected; receive personalized exercise prescriptions automatically generated by the LLM-based system; and provide subjective evaluations on the feasibility and executability of the prescriptions.

Interventions

None listed

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18-75 years with early-stage breast cancer who have undergone surgical treatment, such as mastectomy or breast-conserving surgery. * The patients had clear clinical diagnosis and complete electronic medical record information (including demographic information, tumor stage and classification, treatment history, physical performance evaluation data, etc.).

Exclusion criteria

* Presence of severe postoperative complications or comorbidities (e.g., uncontrolled cardiac or pulmonary disease) that may interfere with participation in rehabilitation or pose a safety risk.

Design outcomes

Primary

MeasureTime frameDescription
Overall Quality Score of Exercise Prescriptions Based on a Five-Dimensional Expert Evaluation FrameworkFrom enrollment to completion of prescription evaluation at 1 weekEach exercise prescription will be independently evaluated by six multidisciplinary experts across five dimensions: scientific rationale, personalization, comprehensiveness, safety, and feasibility. Each dimension will be rated on a 5-point Likert scale from 1 to 5. The five dimension scores will be summed to generate an overall quality score ranging from 5 to 25, with higher scores indicating better overall prescription quality. For each prescription, the mean overall score across the six experts will be used for analysis.

Secondary

MeasureTime frameDescription
Subgroup-Specific Scientific Rationale and Safety Scores of Model-Generated Exercise PrescriptionsFrom enrollment to completion of prescription evaluation at 1 weekModel performance will be evaluated across predefined subgroups based on age, breast cancer stage, molecular subtype, surgical procedure, and treatment modality. Scientific rationale and safety will each be rated on a 1-5 Likert scale, with higher scores indicating better performance. Differences across models and subgroups will be assessed using two-way ANOVA or generalized linear models, including interaction terms between model type and patient characteristics.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026